Bioarray for the Serological Assessment of Immunity Against

Status Recruiting

Clinical Trial Summary

Recent observations in Germany revealed above-average high proportions of refugees affected by infectious diseases of public health significance. Scrutiny of the vaccination status showed sizeable presence of seronegative subjects, with conspicuously higher prevalence among children and adolescents, thus indicating urgent necessity of i) rapid identification of carriers of vaccine-preventable diseases and ii) adjustment of protection against such infections to European Standards. Rapid immune status check needs comprehensive diagnostic tool permitting simultaneous assessment of seropositivity. Validation of such tools requires comparisons of the immune status of subjects with known vaccination history with that of migrants with incomplete or missing health and vaccination records.

Clinical Trial Description

The current massive inflow of refugees and migrants poses urgent necessity of i) rapid identification of carriers of communicable diseases and ii) adjustment of protection against vaccine-preventable infections to European standards. While universal vaccination is supposed to ensure the intended degree of protection, targeted vaccination on the basis of previous assessment of the immune status (seropositivity) was repeatedly shown to be a cost-efficient alternative. Currently, the broad use of immune status assessment prior to targeted vaccination is impeded by the necessity to apply separate seropositivity detection assays for each individual condition. This drawback can be overcome by the introduction of a comprehensive diagnostic tool permitting simultaneous assessment of seropositivity for several vaccine-preventable infections.

The objective of the present study consists in compilation of an array of sera from

- subjects with known history of immunization against vaccine-preventable infections for which vaccines are routinely available (measles, mumps, rubella, varicella, tetanus, pertussis, poliomyelitis, diphtheria, meningococcal infection) and

- new migrants/refugees without reliable vaccination records and undefined immune status to be subsequently used for the validation of a multi-pronged diagnostic tool for seropositivity detection ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03107312
Study type	Observational
Source	Jena University Hospital
Contact	Mathias Pletz, M.D.
Phone	+4936419324667
Email	mathias.pletz@med.uni-jena.de
Status	Recruiting
Phase	N/A
Start date	April 1, 2017
Completion date	March 31, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03854630` - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection	Phase 4
Completed	`NCT04042246` - Effect of Knowledge on Vaccine Take-up in Adamawa State, Northeastern Nigeria	N/A
Enrolling by invitation	`NCT05570630` - VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination	N/A
Completed	`NCT03145324` - Immunisation History Survey - a Study to Measure Levels of Immunity to Routine Immunisations
Recruiting	`NCT06185647` - Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
Recruiting	`NCT05215327` - High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients	Phase 2
Completed	`NCT03355989` - Evaluation of Conditional Cash Transfers (CCTs) for Immunization	N/A
Completed	`NCT02992925` - Phase 3 Study of BK1310 in Healthy Infants	Phase 3
Completed	`NCT03121638` - Safety Study of NBP608 in Healthy Adult Volunteers	Phase 1
Not yet recruiting	`NCT05171946` - Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults	Phase 1
Completed	`NCT05661890` - Seasonal Influenza and Pneumococcal Vaccination in the Elderly
Active, not recruiting	`NCT04444518` - Increasing Influenza and Tdap Vaccination of Pregnant Women	N/A
Active, not recruiting	`NCT03908164` - Optimising the Timing of Whooping Cough Immunisation in MUMs	Phase 4
Completed	`NCT03379467` - Use of SMS and Interactive Reminders to Improve Timely Immunization Coverage	N/A
Not yet recruiting	`NCT03402646` - Mobile Phone Reminders (and Photovoice) for Routine Immunization in Nigeria - The MOPING Study	N/A
Completed	`NCT04824638` - BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers	Phase 2
Recruiting	`NCT05774093` - Evaluation of COVID-19 Immune Barrier and Reinfection Risk
Completed	`NCT03083158` - Immunity to Hepatitis B Vaccine	Phase 4
Recruiting	`NCT04816760` - Immune Cells Phenotypes During COVID-19
Completed	`NCT04870021` - Hepatitis B Birth Dose for Newborns	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Bioarray for the Serological Assessment of Immunity Against Vaccine-preventable Infections — StikoSero

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms